Inventor

Robert McDowell

Inventor

San Francisco, CA, US

Overview

1993–2021

Patent span

Chemistry

Primary field (CPC C)

Patents· 65 as inventor

Public. Assignee & technology derived from the patent record. Each patent links to its LexDana page.

C07Dprimary

C07DHeterocyclic compounds30%

A61PSpecific therapeutic activity of chemical compounds or medicinal preparations25%

A61KPreparations for medical, dental or toiletry purposes19%

C07KPeptides11%

C07CAcyclic or carbocyclic compounds4%

G01NInvestigating or analysing materials by determining their chemical or physical properties3%

C12NMicroorganisms or enzymes3%

Y02ATechnologies for adaptation to climate change2%

Y10STechnical subjects covered by former uspc cross-reference art collections [xracs] and digests1%

C07BGeneral methods of organic chemistry1%

PatentTitleYear

11,123,3374-methylsulfonyl-substituted piperidine urea compounds2021 11,034,690Heterocyclic modulators of lipid synthesis2021 10,758,5254-methylsulfonyl-substituted piperidine urea compounds2020 10,226,449Heterocyclic modulators of lipid synthesis and combinations thereof2019 10,189,822Heterocyclic modulators of lipid synthesis2019 10,118,913Heterocyclic modulators of lipid synthesis2018 10,053,450Heterocyclic modulators of lipid synthesis2018 9,925,177'4-methylsulfonyl-substituted piperidine urea compounds'2018 9,809,591'Heterocyclic modulators of lipid synthesis'2017 9,663,516'Bicyclic-pyrimidinedione compounds'2017 9,624,173'Heterocyclic modulators of lipid synthesis'2017 9,585,883'Pyrimidinedione compounds'2017 9,428,502'Heterocyclic modulators of lipid synthesis'2016 9,199,945'Cycloalkyl-substituted pyrimidinedione compounds'2015 9,181,200'Pyrimidinedione compounds'2015 9,149,463'Methods and compositions of treating a Flaviviridae family viral infection'2015 9,101,628'Methods and composition of treating a flaviviridae family viral infection'2015 9,061,010'Methods of treating a Flaviviridae family viral infection and compositions for treating a Flaviviridae family viral infection'2015 8,895,598'Methods of treating a flaviviridae family viral infection, compositions for treating a flaviviridae family viral infection, and screening assays for identifying compositions for treating a flaviviridae family viral infection'2014 8,871,790'Heterocyclic modulators of lipid synthesis'2014 7,348,333'Cycloalkyl derivatives as inhibitors of bone resorption and vitronectin receptor antagonists'2008 7,259,159'Guanidino derivatives as inhibitors of cell adhesion'2007 7,214,487'Methods for identifying compounds that modulate enzymatic activities by employing covalently bonded target-extender complexes with ligand candidates'2007 7,094,869'Low molecular weight peptidomimetic growth hormone secretagogues'2006 6,919,178'Extended tethering approach for rapid identification of ligands'2005 6,867,208'Vitronectin receptor antagonists, their preparation and their use'2005 6,867,213'(2S)-2-(adamantan-1-ylmethoxycarbonylamino)-3-(4-(2-(1,4,5,6-tetrhydropyrimidin-2-ylcarbamoyl)ethyl)benzoylamino)propionic acid isopropyl ester, its preparation and its use'2005 6,806,279'Small-molecule inhibitors of interleukin-2'2004 6,747,148'Sulfonamide derivatives as inhibitors of bone resorption and as inhibitors of cell adhesion'2004 6,660,728'Thienyl substituted acylguanidines as inhibitors of bone resorption and vitronectin receptor antagonists'2003 6,620,820'Inhibitors of bone reabsorption and antagonists of vitronectin receptors'2003 6,566,366'Thienyl substituted acylguanidines as inhibitors of bone resorption and vitronectin receptor antagonists'2003 6,525,022'Receptor specific atrial natriuretic peptides'2003 6,492,356'Acylguanidine derivatives as inhibitors of bone resorption and as vitronectin receptor antagonists'2002 6,482,821'Vitronectin receptor antagonists, their preparation and their use'2002 6,459,001'Tricyclic compounds, their preparation process and the intermediates of this process, their use as medicaments and the pharmaceutical compositions containing them'2002 6,399,620'Cycloalkyl derivatives as inhibitors of bone resporption and vitronectin receptor antagonists'2002 6,387,895'Vitronectin receptor antagonists, their preparation and their use'2002 6,344,439'Agents for promoting bone formation'2002 6,339,082'Tricyclic compounds, preparation method and said method intermediates, application as medicines and pharmaceutical compositions containing same'2002 6,313,119'Sulfonamide derivatives as inhibitors of bone resorption and as inhibitors of cell adhesion'2001 6,277,845'Hydrazono-benzazulene derivatives, pharmaceutical compositions and intermediates'2001 6,271,198'Constrained helical peptides and methods of making same'2001 6,221,907'Tricyclic compounds having activity specific for integrins, particularly alphanubeta3 integrins, method for preparing same, intermediates therefor, use of said compounds as drugs, and pharmaceutical compositions containing same'2001 6,218,415'Inhibitors or bone reabsorption and antagonists of vitronectin receptors'2001 6,218,387'Vitronectin receptor anatagonists, their preparation and their use'2001 6,207,663'Vitronectin receptor antagonists, their preparation and use'2001 6,194,380'Agents for promoting bone formation'2001 6,034,216'Low molecular weight peptidomimetic growth hormone secretagogues'2000 6,011,045'Vitronectin receptor antagonists, their preparation and their use'2000 6,005,117'Imino compounds, process for their preparation and their use as victronectin antagonists'1999 5,990,145'Vitronectin receptor antagonists, their preparation and their use'1999 5,846,932'Receptor specific atrial natriuretic peptides'1998 5,843,941'Ras farnesyl transferase inhibitors'1998 5,798,337'Low molecular weight peptidomimetic growth hormone secretagogues'1998 5,756,452'Platelet aggregation inhibitors having high specificity for GP II.sub.b III.sub.a'1998 5,674,865'Nonpeptidyl integrin inhibitors having specificity for the GPII.sub.b III.sub.a'1997 5,674,863'Nonpeptidyl integrin inhibitors having specificity for the GPII.sub.b III.sub.a receptor'1997 5,665,704'Receptor specific atrial natriuretic peptides'1997 5,663,166'Nonpeptidyl integrin inhibitors having specificity for the GPII.sub.b III.sub.a receptor'1997 5,565,449'Nonpeptidyl integrin inhibitors having specificity for the GPII.sub.b III.sub.a receptor'1996 5,532,359'Ras farnesyl transferase inhibitors'1996 5,493,007'Platelet aggregation inhibitors having high specificity for GPIIBIIIA'1996 5,403,836'Benzazepine platelet aggregation inhibitors having specificity for the GPII.sub.b III.sub.a receptor'1995 5,250,679'Nonpeptidyl platelet aggregation inhibitors having specificity for the GPII.sub.b III.sub. receptor'1993

Career & activity timeline

Assembled from patent assignee/location history and declaration credentials.

1993–2007Patents assigned to GENENTECH INC (36)· patent assignee history

1993–2021Based in San Francisco, CA, US· patent location history

1999–2005Patents assigned to HOECHST AG (10)· patent assignee history

2001–2005Patents assigned to AVENTIS PHARMA GMBH (5)· patent assignee history

2003Based in San Bernardino, CA, US· patent location history

2014–2019Patents assigned to 3 V BIOSCIENCES INC (5)· patent assignee history

2015–2021Patents assigned to MYOKARDIA INC (7)· patent assignee history

2019Based in Menlo Park, CA, US· patent location history

Inventor activity

Assignee and location history derived from the patent record.

Assignees

Assignee	Patents	Span
GENENTECH INC	36	1993–2007
HOECHST AG	10	1999–2005
MYOKARDIA INC	7	2015–2021
3 V BIOSCIENCES INC	5	2014–2019
AVENTIS PHARMA GMBH	5	2001–2005

Locations

Location	Patents	Span
San Francisco, California, US	61	1993–2021
Menlo Park, California, US	2	2019
San Bernardino, California, US	2	2003